Natalya A. Votyakova

Natalya A. Votyakova

Auto-generated profile, based on publicly available information

Natalya A. Votyakova

N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 December 2024 in Pediatria. Journal named after G.N. Speransky
Verified
Journal Article
Closed access
SMS.V. Mikhaylova
S.V. Mikhaylova
EZEKATERINA ZAKHAROVA
EKATERINA ZAKHAROVA
MZM.V. Zazhivikhina
M.V. Zazhivikhina
NVN.A. Votyakova
N.A. Votyakova
MAM.E. Abdullina
M.E. Abdullina
EPE.E. Petryaykina
E.E. Petryaykina
Pyruvate dehydrogenase complex deficiency (PDC) is a mitochondrial disease associated with a violation of pyruvate metabolism and leading to a decrease in ATP production. PDC is responsible for the decarboxylation of pyruvate into acetyl-CoA. PDC deficiency can be caused by changes in any of the genes encoding its subunits. The clinical phenotype is very variable, mainly the central nervous system is affected. Diagnosis of the disease can cause significant difficulties due to the rarity of the pathology, the lack of specificity of clinical symptoms and pronounced clinical polymorphism. The purpose of this research was to describe and discuss the clinical, biochemical and genetic data of six recently observed patients with PDC deficiency who were identified in Russia. Authors have analyzed the clinical manifestations of a rare progressive pathology from the group of mitochondrial diseases caused by pathogenic variants of the nuclear X-linked PDHA1 gene (encodes the alpha subunit of pyruvate dehydrogenase) in six patients aged 8 to 120 months old. By the time of examination in the hospital the main clinical symptoms included as follows: delayed psychomotor development, epileptic seizures, severe delay in psychomotor development and - in a single patient - depression of consciousness to coma, the status of epileptic seizures and an unfavorable outcome. In all patients, magnetic resonance imaging (MRI) of the brain revealed changes as follows: cortical atrophy in all 6 patients, basal ganglia lesion in three cases, congenital brain defects in 3 patients and multicystic lesion in a single patient. All children had high lactate levels. Pathogenic variants of the PDHA1 gene were detected in all 6 children and on this basis the diagnosis was confirmed. As a result of treatment, 5 of the 6 children showed moderate positive dynamics as follows: a decrease in the frequency of epileptic seizures and lactate in the blood, improvement in psychomotor development and - in a single patient - a fatal outcome as a result of late diagnosis and rapidly progressing clinical symptoms. Conclusion: Authors have described the clinical characteristics of PDC in recent cases such as: age of manifestation, the disease course nature, results of molecular genetic studies. Clinical polymorphism in patients with this rare pathology was shown as well. The Article may be of great help to pediatricians, neurologists and geneticists in improving the diagnosis of PDC deficiency.

30 April 2026 in Russian Journal of Child Neurology
Verified
Journal Article
Open access
SMSvetlana V. Mikhaylova
Svetlana V. Mikhaylova
MAM. E. Abdullina
M. E. Abdullina
NVN. A. Votyakova
N. A. Votyakova
MZM. V. Zazhivikhina
M. V. Zazhivikhina
EUE. L. Usacheva
E. L. Usacheva
EPE. E. Petryaykina
E. E. Petryaykina
Progressive Duchenne muscular dystrophy is a severe progressive X-linked hereditary disease caused by mutations in the DMD gene encoding the dystrophin protein. The disease is characterized by early onset of muscle weakness in the proximal limbs, loss of the ability to walk independently, followed by damage to respiratory and cardiac functions, and premature death of patients in the second or third decade of life. Until recently, patients were prescribed only symptomatic treatment aimed at slowing down the progression of the disease. Currently, several pathogenetic drugs have appeared aimed at restoring the synthesis of the dystrophin protein (microdystrophin). One of them, delandistrogen moxparvovec, is gene therapy drug based on a recombinant adeno-associated virus (AAVhr74). The article presents the experience of using Delandistrogen moxparvovec in 17 patients with Duchenne muscular dystrophy aged 5 years 8 months to 9 years and 1 months. Preliminary data indicate a possible slowdown in the progression of the disease, which is manifested in stabilization or improvement of motor functions. In all patients, the use of this drug was safe, there were no adverse events associated with this therapy.

31 August 2025 in Clinical nutrition and metabolism
Verified
Journal Article
Open access
PDF file
AAAnna A. Agafonova
Anna A. Agafonova
SMSvetlana V. Mikhaylovna
Svetlana V. Mikhaylovna
NVNatalya A. Votyakova
Natalya A. Votyakova
MZMayya V. Zazhivikhina
Mayya V. Zazhivikhina
LMLarisa I. Minaycheva
Larisa I. Minaycheva
ЗВЗаживихина Майя Владимировна
Заживихина Майя Владимировна
BACKGROUND: Although homocystinuria is a rare disorder, its management remains an important issue in modern pediatrics. Diet therapy is the main pathogenetic treatment for patients with homocystinuria. The use of betaine as part of combination therapy helps reduce plasma homocysteine concentrations, particularly in patients who do not respond to other treatment approaches. A CASE REPORT: A 12-year-old child with genetically confirmed pyridoxine-responsive homocystinuria underwent substitution of an imported preparation containing anhydrous betaine with a specialized medical nutrition product, Amino Acid Module Betaine (ORPHANIC® trademark). The previously effective combination therapy regimen remained unchanged. CONCLUSION: Replacement of anhydrous betaine within the previously established treatment regimen, followed by 30 days of administration of the medical nutrition product Amino Acid Module Betaine (ORPHANIC® trademark) containing betaine anhydrous, demonstrated a good safety profile. This substitution did not significantly affect the patient’s general condition, disease course, or key parameters of sulfur-containing amino acid metabolism. Prescription of the medical nutrition product Amino Acid Module Betaine (ORPHANIC® trademark) containing anhydrous betaine, or transition of a patient to this product, requires monitoring of the patient’s general condition and regular determination of sulfur-containing amino acid metabolism parameters. This study represents the first clinical evaluation of anhydrous betaine produced in Russia. The obtained results indicate its efficacy and safety in the treatment of a patient with homocystinuria.